×

Tag: Maximon

Biotech investment
Maximon, Marcuard Heritage, and GenTwo have announced the launch of a new longevity-related investment opportunity. Their proposal allows professional investors to get access to Maximon's portfolio of longevity companies via an actively managed certificate (AMC). According to Maximon, there have been many requests to launch an AMC focused on longevity. Therefore, Marcuard Heritage, a top...
Longevity Investors Conference
This leading investors-only conference in the longevity field will bring together the world's most renowned longevity experts and private and institutional investors in the heart of the Swiss Alps. Zug, June 14, 2022 - Longevity Investors Conference (LIC) has the honour of welcoming leading longevity experts and scientists such as George Church (Professor of Genetics, Harvard...
AVEA Founders
The longevity company builder Maximon has concluded a financing round for AVEA at this year's World Economic Forum. The press release is included here. ZUG, SWITZERLAND — AVEA, the longevity supplement startup with the aim to improve healthspan, announces the closing of a 2.5 million CHF seed financing round led by Maximon, The Longevity Company...
Maximon logo
The investment firm Maximon is awarding a prize of 50,000 Swiss francs to an organization that Maximon believes has engaged in research that is likely to improve healthspan and lifespan in humans. The full press release is provided here. Maximon, Europe’s first longevity company builder, is launching the Maximon Longevity Prize for Translational Research, awarding...
Tobias Reichmuth EARD2021
At Ending Age-Related Diseases 2021, Tobias Reichmuth of Maximon taught aspiring enterpreneurs ten critical rules for developing their own longevity companies. Script What I have to talk about today is maybe a bit different from many other speeches. I really want to shed some light on what we at Maximon believe is very important when...
Maximon logo
The venture capitalist firm Maximon has announced a new longevity-focused fund that focuses on financing early-stage biotechnology companies that increase human healthspan. The firm intends to invest 100 million Swiss francs into such companies. The full press release is presented below. Maximon has launched its 100 million Longevity Co-Investment Fund The Longevity Co-Investment Fund finances...